Diabetes Vaccine Market Analysis & Forecast: 2026-2033
The Diabetes Vaccine Market size is anticipated to grow at a CAGR of 8% with USD 89.6 Mn in 2026 and is expected to reach USD 153.3 Mn in 2033. The primary drivers are defined by the rising incidence of type 1 diabetes, expanding autoimmune-disease research, increasing clinical development of antigen-specific immunotherapies, and growing demand for treatments that preserve pancreatic beta-cell function. According to the International Diabetes Federation, approximately 9.2 Mn people worldwide live with type 1 diabetes, including 1.8 Mn children and adolescents. This is accelerating investment in tolerogenic vaccines, peptide-based candidates, DNA vaccines, mRNA platforms, and immune-modulating therapies across biotechnology companies, research institutes, specialized hospitals, academic centers, and global clinical trial networks.
On the basis of age group, the up to 20 years of age segment is projected to account for the largest Diabetes Vaccine Market share of 58.7% in 2026. The segment’s growth is owing to the high pediatric burden of type 1 diabetes and increasing emphasis on preventing or delaying autoimmune beta-cell destruction before lifelong complications emerge.
According to the CDC’s 2026 National Diabetes Statistics Report, about 314,000 of the U.S. children and adolescents below 20 years are living with diagnosed type 1 diabetes, thereby creating a target population for preventive and immune-modulating approaches. The rising screening rates, earlier diagnosis, and greater clinical focus on preserving insulin production are strengthening the demand for antigen-specific vaccines, immune-tolerance therapies, as well as early intervention programs.
ClinicalTrials.gov also lists an ongoing study of repeat Bacillus Calmette–Guérin vaccination in children aged 8 to under 18 years with newly diagnosed type 1 diabetes, evaluating effects on HbA1c, insulin requirements, and metabolic outcomes over time.
To learn more about this report, Request Free Sample
On the basis of end user, the hospitals segment lead with a major 61.5% share in 2026. The growth is owing to the central role in identifying high-risk patients, confirming type 1 diabetes stages, administering immune-modifying therapies, conducting vaccine trials, and monitoring adverse events and metabolic responses.
According to the CDC’s 2026 National Diabetes Statistics Report, approximately 2.1 million people in the U.S. have diagnosed type 1 diabetes, thereby creating a substantial patient base for hospital-based screening and intervention. The CDC also reports that around 30%–40% of U.S. children present with diabetic ketoacidosis at initial diagnosis often requiring urgent hospitalization.
Growing clinical development is transforming the diabetes vaccine market by shifting attention beyond conventional glucose control. Antigen-specific approaches are being investigated to preserve pancreatic beta-cell function and modify autoimmune disease progression.
The clinical stage activity in the diabetes vaccine market is represented by the MER3101 program. ClinicalTrials.gov describes MER3101 as a Phase I, randomized, placebo-controlled study which evaluates an MAS-1-adjuvanted islet beta-cell antigen formulation. It is intended to promote tolerogenic immune pathways in people at risk of or affected by type 1 diabetes. The study record was updated in February 2026 and is listed as completed. This demonstrates continual progress in immune-directed diabetes prevention as well as treatment research.
The findings from this program may support the future vaccine development, patient selection, dosing strategies, as well as larger clinical trials aimed at delaying disease onset and reducing long-term dependence on insulin therapy.
Antigen-specific immunotherapy represents one of the most important emerging technologies in the diabetes vaccine market. Unlike traditional infectious-disease vaccines that stimulate protective immunity against external pathogens, most therapeutic diabetes vaccine candidates seek to reduce or redirect harmful immune responses against the body’s insulin-producing beta cells. Some of the investigated targets include insulin, proinsulin, GAD65, IA-2, and combinations of beta-cell peptides. Technologies under evaluation include recombinant proteins, synthetic peptides, DNA plasmids, antigen-adjuvant combinations, nanoparticles, as well as tolerogenic immune-cell treatments.
DNA-based immunotherapy is also advancing. A Phase I study published in March 2026 assessed an islet-antigen-specific plasmid encoding preproinsulin and immunoregulatory proteins in adults with type 1 diabetes. The study involved 47 adults and was designed to evaluate safety, tolerability, and pharmacodynamic activity. The treatment was generally reported as safe and well tolerated, but larger trials are needed to determine whether the platform can preserve beta-cell function or reduce insulin dependence.
|
Current Event |
Description and its Impact |
|
Full Implementation of the EU Clinical Trials Regulation in 2025 |
|
|
FDA Master Protocol and Clinical Development Modernization in 2026 |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 39.8% of the market share in 2026. The region’s growth is owing to the large type 1 diabetes population, advanced clinical-trial networks, access to autoantibody testing, strong biotechnology investment, and an established regulatory pathway for disease-modifying treatments.
The International Diabetes Federation estimates that approximately 1.48 million people of all ages were living with type 1 diabetes in the U.S. in 2024. The IDF also estimates that the country incurred approximately USD 404.5 billion in total diabetes-related health expenditure during the year 2024. This demonstrates the scale of the country’s healthcare burden and treatment infrastructure.
In March 2026, GentiBio dosed the first participant in its Phase I POLARIS study of GNTI-122. The study is enrolling through 10 specialized U.S. clinical sites and is evaluating an autologous engineered regulatory T-cell therapy in adults treated within 120 days of type 1 diabetes diagnosis.
Asia Pacific is expected to witness strong growth in market over the forecast period. The region’s growth is owing to the large patient populations, increasing diabetes awareness, expanding private hospital systems, improving endocrinology capacity, and greater participation in multinational clinical research.
India represents a significant long-term opportunity. The IDF estimates that approximately 940,840 people of all ages were living with type 1 diabetes in India in 2024, including approximately 300,788 children and adolescents below 20 years. India also had approximately 89.8 million adults aged 20–79 years living with all forms of diabetes, thereby demonstrating its extensive diabetes-related healthcare requirements.
A notable pipeline development is the SAFEGUARD Phase 2b trial of SAB-142, listed in the Australian New Zealand Clinical Trials Registry and updated in July 2026. The study is evaluating whether the immune-targeted therapy can delay disease progression and preserve C-peptide production in patients aged 5–40 years with newly diagnosed stage 3 type 1 diabetes.
In Canada, the Diabetes Vaccine Market is influenced by the rising diabetes burden along with the progress in preventive immunotherapy. The Public Health Agency of Canada data show that about 3.9 million people aged over one year live with diagnosed diabetes, thus representing 9.7% of the population. This sizeable patient pool is supporting screening, prevention, and disease-modifying research particularly for type 1 diabetes.
In April 2026, the Government of Canada’s Meds Pipeline Monitor highlighted Diamyd, a GAD65-based antigen-specific immunotherapy for type 1 diabetes, undergoing clinical development in Canada. Its ongoing Phase III trial is evaluating the treatment’s ability to preserve insulin-producing beta-cell function, with completion expected in 2027.
China’s Diabetes Vaccine Market is growing with a rapid pace. The rising disease prevalence is increasing the demand for preventive and immune-modulating therapies. In February 2025, the Shanghai municipal government reported that latest 2024 national data placed adult diabetes prevalence in China at approximately 12%, thereby highlighting a substantial target population for disease-modifying interventions.
In February 2025, Diamyd Medical expanded its partnership with Breakthrough T1D, securing USD 1.75 million to support the Phase 3 DIAGNODE-3 trial of Diamyd, an antigen-specific therapeutic vaccine designed to preserve insulin production in type 1 diabetes. Diamyd’s relevant administration patent is already protected in China, supporting potential future market entry and strengthening interest in precision vaccines, clinical collaboration, and commercialization across China.
Some of the major key players in Diabetes Vaccine Market are Diamyd Medical AB, Vactech Oy, Novo Nordisk A/S, Imcyse SA, COUR Pharmaceuticals Development Company, Inc., Precigen, Inc., Nova Immunotherapeutics Limited, AnTolRx, Inc., AviSia Therapeutics B.V.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 89.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8% | 2033 Value Projection: | USD 153.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Diamyd Medical AB, Vactech Oy, Novo Nordisk A/S, Imcyse SA, COUR Pharmaceuticals Development Company, Inc., Precigen, Inc., Nova Immunotherapeutics Limited, AnTolRx, Inc., AviSia Therapeutics B.V. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
